Development And Characterization Of Nanoparticles Containing 5-Fluorouracil In DNA Damage And Repair Genes For Head And Neck Cancer
Keywords:
Nanoparticles, 5-Fluorouracil, Cancer, Ionic gelation, Targeted therapy, Hyaluronic acid conjugation, In vivo pharmacokineticsAbstract
This research aims to develop an innovative approach to the construction of a nanocarrier system specifically designed for the delivery of medicines to the colon. As a powerful tool for the fight against colorectal cancer, 5-Fluorouracil (5-FU) was optimized by using natural and gastrointestinal polymers. There are several limitations to the traditional delivery of 5-FU to its target, which has led to the exploration of new delivery methods. By formulating 5-FU-loaded polymer nanoparticles, we carefully characterized their physical chemical properties. In addition to overcoming existing challenges, our goal was to increase the availability of drugs in the colon. Initial analyses using Fourier transform infrared (FT-IR) and differential scanning calimetry (DSC) confirmed that 5-FU is compatible with chitosan. Furthermore, we observed that the drug encapsulated in the nanoparticles took on an amorphous state, increasing its effectiveness. Our rigorous statistical analysis of in vivo pharmaceutical parameters has yielded promising results. The ion gelation method that we have used to design our new nanoparticle drug delivery system has demonstrated its organic appeal as a solvent-free and simpler alternative. Our nanoparticles have also been enhanced in targeting precision by adding hyaluronic acid. In addition, the quality and consistency of our core tablets with 5-FU were assured by comprehensive characterization data, including particle size, morphology, capture efficiency and more. In addition to proving that chitosan is a biocompatible and biodegradable material, this innovative approach also indicates the feasibility of using it in the treatment of colon cancer. Furthermore, hyaluronic acid improves target accuracy, while the scalability and reproducibility of ionic gelation make it even more attractive. Clinical trials are necessary to determine whether these formulations are effective and safe. Our approach is to show a path towards more effective and sustainable drug delivery systems that can revolutionize the treatment of colorectal cancer using natural polymers and colon-specific polymers
References
J. A. Hubbell, "Materials science: enhancing drug function," Science, vol. 300, pp. 595–596, 2003.
C. Cai, K. Zhou, Y. Wu, and L. Wu, "Enhanced liver targeting of 5-fluorouracil using galactosylated human serum albumin as a carrier molecule," J. Drug Target., vol. 14, pp. 55–61, 2006.
S. Cao and Y. M. Rustum, "Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose," Cancer Res., vol. 60, pp. 3717–3721, 2000.
T. Kubota, "Recent progress in combination therapy of low-dose CDDP/5-FU in Japan. Theoretical basis for low-dose CDDP/5-FU therapy," Jpn. J. Cancer Chemother., vol. 26, pp. 1536–1541, 1999.
W. R. Shapiro et al., "A randomized comparison of intra-arterial versus intravenous with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma," J. Neurosurg., vol. 76, pp. 772–781, 1992.
L. F. Hutchins et al., "Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102," J. Clin. Oncol., vol. 23, pp. 8313–8321, 2005.
D. B. Longley, D. P. Harkin, and P. G. Johnston, "5-fluorouracil: mechanisms of action and clinical strategies," Nat. Rev. Cancer, vol. 3, pp. 330–338, 2003.
W. B. Parker and Y. C. Cheng, "Metabolism and mechanism of action of 5-fluorouracil," Pharmacol. Ther., vol. 48, pp. 381–395, 1990.
F. Fata et al., "5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma," Cancer, vol. 86, pp. 1129–1134, 2000.
D. Paolo et al., "Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients," Ann. Oncol., vol. 12, pp. 1301–1306, 2001.
A. B. P. van Kuilenburg et al., "Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene," Clin. Cancer Res., vol. 6, pp. 4705–4712, 2000.
M. Boisdron-Celle, M. P. Croué, and J. P. Benoit, "Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers," J. Pharm. Pharmacol., vol. 47, p. 108, 1995.
S. H. Cho and H. B. Lee, "Preparation of 5-fluorouracil-loaded poly (L-lactide-co-glycolide) wafer and evaluation of in vitro release behavior," Macromol. Res., vol. 11, pp. 183–188, 2003.
G. Wang et al., "In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly (D, L-lactide-co-glycolide)," Pharm. Res., vol. 13, pp. 1059–1064, 1996.
J. S. Lee et al., "Degradation behaviour in vitro for poly (D, L-lactide-co-glycolide) as drug carrier," Biomed. Mater. Eng., vol. 14, pp. 185–192, 2004.
K. Makino et al., "Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin," Colloids Surf. B Biointerfaces, vol. 36, pp. 35–42, 2004.
J. Yoo et al., "Effect of lactide/glycolide monomers on release behaviors of gentamicin sulfate-loaded PLGA discs," Int. J. Pharm., vol. 276, pp. 1–9, 2004.
L. F. Lemaire et al., "Therapeutic efficacy of 5-fluorouracil-loaded microspheres on rat glioma: a magnetic resonance imaging study," NMR Biomed., vol. 14, pp. 360–366, 2001.
P. Menei et al., "Local and sustained delivery of 5 fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma," Cancer, vol. 86, pp. 325–330, 1999.
J. H. Kim et al., "Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice," J. Control. Release, vol. 127, pp. 41–49, 2008.
K. K. Upadhyay et al., "The intracellular drug delivery and antitumor activity of doxorubicin loaded poly ([gamma]-benzyl l-glutamate)-b-hyaluronan polymersomes," Biomaterials, vol. 31, pp. 2882–2892, 2010.
Z. Zhu et al., "Paclitaxel-loaded poly (N-vinylpyrrolidone)-b-poly ([epsilon]-caprolactone) nanoparticles: preparation and antitumor activity in vivo," J. Control. Release, vol. 142, pp. 438–446, 2010.
S. Li et al., "Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles," BMC Cancer, vol. 8, pp. 103–111, 2008.
V. Selvaraj and M. Alagar, "Analytical detection and biological assay of antileukemic drug 5-fluorouracil using gold nanoparticles as probe," Int. J. Pharm., vol. 337, pp. 275–281, 2007.
D. Baskic et al., "Analysis of cyclohex-imide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide," Cell Biol. Int., vol. 30, pp. 924–932, 2006.
D. Ribble et al., "A simple technique for quantifying apoptosis in 96-well plates," BMC Biotechnol., vol. 5, pp. 12, 2005.
C. Kuropkat et al., "Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report," Am. J. Clin. Oncol., vol. 22, pp. 466–470, 1999.
P. M. De Angelis et al., "Cellular response to 5-fluorouracil(5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery," Mol. Cancer, vol. 5, pp. 20–45, 2006.
Y. C. He et al., "Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats," World J. Gastroenterol., vol. 9, pp. 1795–1798, 2003.
E. Fournier et al., "Development of novel 5-FU-loaded poly (methylidene malonate 2.1. 2)-based microspheres for the treatment of brain cancers," Eur. J. Pharm. Biopharm., vol. 57, pp. 189–197, 2004.
E. Fournier et al., "Therapeutic effectiveness of novel 5 fluorouracil loaded poly (methylidene malonate 2.1. 2) based microspheres on F98 glioma bearing rats," Cancer, vol. 97, pp. 2822–2829, 2003.
S. Desgouilles et al., "The design of nanoparticles obtained by solvent evaporation: a comprehensive study," Langmuir, vol. 19, pp. 9504–9510, 2003.
A. Jain and S. K. Jain, "In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors," Eur. J. Pharm. Sci., vol. 35, pp. 404–416, 2008.